logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Burosumab for x-linked hypophosphataemia in adults

< Back

Burosumab for x-linked hypophosphataemia in adults

Drugs

Haematology and Blood Products

July 2020


Burosumab is in clinical development for the treatment of adults with X-linked hypophosphataemia (XLH), and is currently licenced in children. XLH is an inherited disorder characterized by low levels of phosphate in the blood. Phosphate levels are low because phosphate is abnormally processed in the kidneys due to high levels of a protein called FGF23, which causes a loss of phosphate in the urine (phosphate wasting) and leads to soft, weak bones (rickets). For the past 40 years, therapy has primarily consisted of multiple daily doses of oral phosphate with active vitamin D. Due to adverse effects of this conventional therapy, the general practice and guidance has been to stop treatment at the end of growth and only treat adult patients who are symptomatic with XLH, leaving a substantial proportion of adults with no treatment.

Burosumab, administered by subcutaneous injection, is a monoclonal antibody (a type of protein) designed to recognise and attach to the FGF23 protein. By attaching to the FGF23 protein, the medicine blocks its activity, allowing the kidneys to reabsorb phosphate into the bloodstream and restore normal levels of phosphate in the blood. In studies of adults with XLH, burosumab is associated with normalisation of serum phosphorus, restoration of bone quality and improvements in pain, stiffness, fatigue, as well as healing of fractures compared to placebo.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts